The porphyrin-acridine conjugates (22) and (23) were prepared by condensation of porphyrin (17) with the 9-aminoacridine derivative (6) or (15), respectively. The conjugate drugs were isolated by size-exclusion chromatography in yields of up to 35% and further purified by semipreparative h.p.l.c . to 98% purity. Characterization of the conjugates was effected by 1H n.m.r. and u.v./vis . spectroscopy, f.a.b. mass spectrometry and u.v./vis . diode array h.p.l.c. Attempts to condense acridine (6) or (15) to porphyrin (16), (18) or (19) resulted in the isolation of the porphyrin-acridine conjugates (20), (21), (24) and (25) in low yields (≤ 25%), but the products could not be obtained in a pure state. However, their presence was identified by several physical measurements.
卟啉(17)分别与 9-氨基吖啶衍生物(6)或(15)缩合,制备出卟啉-吖啶共轭物(22)和(23)。共轭药物通过尺寸排阻色谱法分离,产率高达 35%,并通过半分离高效液相色谱法进一步纯化,纯度达 98%。通过 1H n.m.r. 和 u.v./vis .光谱法、f.a.b. 质谱法和 u.v./vis .二极管阵列 h.p.l.c. 法对共轭物进行了表征。尝试将吖啶 (6) 或 (15) 与卟啉 (16)、(18) 或 (19) 缩合后,分离出了卟啉-吖啶共轭物 (20)、(21)、(24) 和 (25),产率较低(≤ 25%),但这些产物无法以纯物状态获得。不过,通过几种物理测量方法确定了它们的存在。